Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Description

This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

Conditions

Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

Intensity-Modulated Stereotactic Radiotherapy as an Upfront Scalp-Sparing Intervention for the Treatment of Newly Diagnosed Grade II-IV Gliomas

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Condition
Glioblastoma
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States, 19107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must have histologically confirmed low or high grade glioma (grade II-IV)
  • * Karnofsky performance status (KPS) \>= 60
  • * Patients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment
  • * Estimated survival \>= 3 months
  • * Labs considered acceptable per standard of care
  • * Patient must sign a study specific informed consent form
  • * Radiation treatment must begin \>= 3 weeks and =\< 8 weeks after surgery
  • * Prior history of scalp radiation or intolerance to standard course of radiation treatment
  • * Co-morbidities that would influence wound healing including diabetes (insulin dependent) or smoking (current ongoing use)
  • * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
  • * Karnofsky performance status (KPS) \< 60
  • * Patient can't have magnetic resonance imaging (MRI) scan
  • * Active collagen vascular disease

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sidney Kimmel Cancer Center at Thomas Jefferson University,

Wenyin Shi, MD, PRINCIPAL_INVESTIGATOR, Thomas Jefferson University

Study Record Dates

2025-12-31